Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 41Active not recruiting 33Completed 14Terminated 4Not yet recruiting 2Withdrawn 1Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Oropharyngeal Neoplasms 1Carcinoma 1

Interventions

Specimen Handling 33Magnetic Resonance Spectroscopy 21Biopsy 19Cyclophosphamide 10venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Vincristine 5Etoposide 5Bevacizumab 5fludarabine phosphate 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Injections 4Doxorubicin 4Cisplatin 4fludarabine 3durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Leucovorin 3Irinotecan 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × 1,2-diaminocyclohexaneplatinum II citrate × 1 year × Clear all
NCT05050162 2026-05-07

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NRG Oncology

Phase 2/3 Suspended
1,714 enrolled
Head & Neck

Carcinoma, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡